Quimioterapia con estramustina en el manejo del cáncer de próstata resistente a la castración: metaanálisis de ensayos controlados aleatorizados

According to this meta-analysis, chemotherapy with additional estramustine increased the PSA response rate. However, it increased the risk of grade 3 or 4 adverse effects such as nausea/vomiting and cardiovascular events, and the overall survival was not improved for castration-resistant prostate cancer patients.